Abstract
The underlying cause of acute myocardial infarction can now be effectively treated with thrombolytic agents, thereby increasing myocardial salvage and reducing mortality. Clinicians should always be aware of the risk-to-benefit ratio in treating patients with thrombolytic agents and treat each patient on an individual basis.
MeSH terms
-
Acute Disease
-
Anistreplase / administration & dosage
-
Aspirin / therapeutic use
-
Clinical Trials as Topic
-
Contraindications
-
Heparin / therapeutic use
-
Humans
-
Myocardial Infarction / drug therapy*
-
Streptokinase / administration & dosage
-
Thrombolytic Therapy*
-
Time Factors
-
Tissue Plasminogen Activator / administration & dosage
Substances
-
Anistreplase
-
Heparin
-
Streptokinase
-
Tissue Plasminogen Activator
-
Aspirin